Default Rate

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A new AI trading bot promises hands-free profits, but a lack of regulatory oversight and performance data raises critical questions for new investors.

A Yale spinout's AI-powered EEG platform promises to prevent birth injuries and cut C-sections by monitoring the fetal brain, not just heart rate.

As Sri Lanka emerges from its economic crisis, a first-of-its-kind European-regulated fund provides a liquid, secure path to its undervalued assets.

A critical vulnerability in the OpenClaw AI agent allowed any website to silently hijack developer tools, exposing a new and dangerous class of security risks.

Following a devastating school shooting, a national mental health provider offers a free crisis line, highlighting the urgent need for trauma support.